RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Craig Wong-Pan maintains a Sector Perform rating on ResMed (NYSE:RMD) and raises the price target from $187 to $200.
April 26, 2024 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Craig Wong-Pan maintains a Sector Perform rating on ResMed and raises the price target from $187 to $200.
The increase in price target by RBC Capital suggests a positive outlook on ResMed's stock, potentially leading to increased investor confidence and a short-term upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 90